SAN FRANCISCO — Moderna Therapeutics had record-setting success raising money from private investors, but the much-discussed biotech has struggled to convince the public markets of its industry-upending potential, and its stock price has slumped nearly 30 percent in the weeks following what was biotech’s largest-ever initial public offering.

That left Moderna CEO Stéphane Bancel, speaking before a standing-room crowd at the industry’s premiere gathering on Tuesday, with a curious task: convincing investors that his $5 billion company is actually undervalued.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I looked at Moderna’s webpage and am scratching my head about their strategy. They give the impression that they have discovered this new stuff, called RNA, which might be impressive to non-scientists who have never heard of it, but to a scientist? It seems pretty silly to get excited about something that we all know a great deal about…

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy